IWWM-11 2022 | Treatment options for transplant-ineligible lymphoma patients: the growing role of immunotherapies
Stephen Ansell
• 28 Oct 2022
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, gives an overview of treatment options for patients with lymphoma who are ineligible for autologous stem cell transplantation (autoSCT), drawing focus on the growing role of novel targeted therapies and immunotherapies. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding from Seattle Genetics, BMS, Affimed, Regeneron, Takeda, AstraZeneca, Pfizer, ADC Therapeutics to my institution for clinical trials.
